Researchers for this paper summarized the efficacy and tolerability data for intravenous immunoglobin (IVIG) and subcutaneous immunoglobin (SCIG). They included a review of the literature of these two treatments for neurological disorders. According to their findings, IVIG, as the standard treatment, “has been shown to be useful for the treatment of new-onset or recurrent immune diseases and for long-term maintenance treatment of chronic diseases. Moreover, IVIG may have applications in the management of intractable autoimmune epilepsy, paraneoplastic syndrome, autoimmune encephalitis, and neuromyelitis optica.” SCIG, as the alternative treatment of IVIG, had different applications, but despite a lower bioavailability, the homeostasis level was more stable than for IVIG. They noted that both therapies have pharmacodynamic equivalence. “It will be necessary to standardize the use of IVIG in the clinical setting,” they wrote. “SCIG administration is a novel and feasible treatment option for neurologic and immune-related diseases, such as chronic inflammatory demyelinating polyradiculoneuropathy and idiopathic inflammatory myopathies.”

This article was originally published here